Scientific Reports

Table 1 Size of study cohorts for each outcome of interest in primary and alternative analyses.

From: Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis

Outcome	Alendronate				Raloxifene
Outcome	Patients	Person-Years	Events	Rate^a	Patients	Person-Years	Events	Rate^a
Primary analysis
Hip fracture	283,586	1,076,597	8051	7.48	40,463	156,080	1033	6.62
Vertebral fracture	279,497	1,058,734	8659	8.18	40,051	154,031	1134	7.36
Atypical femoral fracture	283,894	1,094,049	1244	1.14	40,503	158,722	109	0.69
Esophageal cancer	283,981	1,096,983	234	0.21	40,482	158,858	35	0.22
Osteonecrosis of jaw	284,079	1,097,499	101	0.09	40,511	158,972	9	0.06
Alternative analysis^b
Hip fracture	185,021	116,262	622	5.35	27,620	17,282	92	5.32
Vertebral fracture	182,025	114,510	719	6.28	27,308	17,066	112	6.56
Atypical femoral fracture	185,258	116,735	85	0.73	27,642	17,345	6	0.35
Esophageal cancer	185,312	116,801	13	0.11	27,625	17,348	\(<6\)	0.23
Osteonecrosis of jaw	185,367	116,838	\(<6\)	0.03	27,649	17,365	0	0

^aRate: incidence per 1,000 person-years.
^bThree data sources excluded from alternative analysis (P-Plus, NHIS NSC, Cerner UT).

Back to article page

Search

Advanced search

Quick links